invoX Pharma Limited
10Patents
10Active
10Granted
48Portfolio score
Filing activity: Jul 12, 2019 → Jun 30, 2023
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US12103976B2 | Fc binding fragments comprising a CD137 antigen-binding site | Chemistry; Metallurgy | 3 | Active |
| US12187761B2 | Compounds, compositions, and methods for the treatment of disease | Emerging Cross-Sectional Technologies | 1 | Active |
| US12344672B2 | Antibody molecules that bind PD-L1 and CD137 | Chemistry; Metallurgy | 0 | Active |
| US12297283B2 | Fc binding fragments comprising an OX40 antigen-binding site | Chemistry; Metallurgy | 0 | Active |
| US12252537B2 | Antibody molecules that bind CD137 and OX40 | Chemistry; Metallurgy | 0 | Active |
| US12325742B2 | Anti-mesothelin antibodies | Chemistry; Metallurgy | 0 | Active |
| US12319739B2 | Mesothelin and CD137 binding molecules | Chemistry; Metallurgy | 0 | Active |
| US12247074B2 | Antibody molecules | Emerging Cross-Sectional Technologies | 0 | Active |
| US12390668B2 | Compounds, compositions, and methods for the treatment of disease | Emerging Cross-Sectional Technologies | 0 | Active |
| US12187798B2 | LAG-3 binding members | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.